Optune by Novocure uses targeted electric fields to disrupt cancer cell division and cause cancer cell death. 500 hospitals globally can prescribe the FDA approved treatment to glioblastoma patients.
“Tumor Treating Fields” are low intensity, alternating electric fields within the intermediate frequency range. TTFields disrupt cell division through physical interactions with key molecules during mitosis. The non-invasive treatment targets solid tumors.
Company founder Yoram Palti said that trials in other tumors will have results starting this year, and he “believes that we will change the way we treat cancer. There are other growths that are more sensitive to our approach than brain cancer. A pilot of 40 lung cancer patients had exciting results in a treatment where the electrodes are only worn 12 hours a day and not 24.”
Click to view Optune US video
Wearable Tech + Digital Health NYC – June 7, 2016 @ the New York Academy of Sciences
NeuroTech NYC – June 8, 2016 @ the New York Academy of Sciences